Nature Medicine
1, 628 - 629 (1995)
doi:10.1038/nm0795-628
Targeting HIV reverse transcriptase in novel waysMark A. Wainberg
& Zhengxian GuMcGill University AIDS Centre, Jewish General Hospital, Montreal Quebec, Canada H3T1E2 The promising description of a potential basis for gene therapy in treating HIV infection does not mean that traditional approaches should be abandoned (pages 667−673).
REFERENCES
- Larder, B.A. & Kemp, S.D. Multiple mutations in HIV-1 reverse transcriptase confer high-level resistance to zidovudine (AZT). Science 246, 1155−1157 (1989). | PubMed | ISI | ChemPort |
- St. Clair, M.H. et al. Resistance to ddI and sensitivity to AZT induced by a mutation in HIV-1 reverse transcriptase. Science 253, 1557−1559 (1991). | PubMed | ChemPort |
- Maciejewski, J.P. et al. Intracellular expression of antibody fragments directed against HIV reverse transcriptase prevents HIV infection in vitro. Nature Med. 1, 667−673 (1995). | Article | PubMed | ISI | ChemPort |
- Zack, J.A. et al. HIV-1 entry into quiescent primary lymphocytes: molecular analysis reveals a labile, latent viral structure. Cell 61, 213−222 (1990). | PubMed | ISI | ChemPort |
- Wu, J., Amandoron, E., Li, X., Wainberg, M.A. & Parniak, M.A. Monoclonal antibody-mediated inhibition of HIV-1 reverse transcriptase polymerase activity. J. biol. Chem. 268, 9980−9985 (1993). | PubMed | ISI | ChemPort |
- Skalka, A.M. & Goff, S.P. (eds). Reverse Transcriptase (Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York, 1993).
- Martin, J.L., Wilson, J.E., Haynes, R.L. & Furman, P.A. Mechanism of resistance of human immunodeficiency virus type 1 to 2',3'-dideoxyinosine. Proc. natn. Acad. Sci. U.S.A. 90, 6135−6139 (1993). | ChemPort |
- Gu, Z., Arts, E.J., Parniak, M.A. & Wainberg, M.A. Mutated K65R recombinant HIV-1 reverse transcriptase shows diminished chain termination in the presence of 2',3'-dideoxycytidine and 5'-triphosphate and other drugs. Proc. natn. Acad. Sci. U.SA. 92, 2760−2764 (1995). | ChemPort |
- Katlama, C., The European Lamivudine HIV Working Group. Combination 3TC (lamivudine) ZDV (zidovudine) vs ZDV monotherapy in ZDV naive HIV-1 positive patients with CD4 of 100−400 cells/mm3. AIDS 8, S6 Abstract 7.5 (1994).
- Staszewski, S., Lamivudine HIV Working Group. Combination 3TC (lamivudine) ZDV (zidovudine) vs ZDV monotherapy in ZDV pre-treated HIV-1 positive patients with CD4 of 100−400 cells/mm3. AIDS 8, S7 Abstract 7.6 (1994).
- Gu, Z., Gao, Q., Li, X., Parniak, M.A. & Wainberg, M.A. A novel mutation in the human immunodeficiency virus type 1 reverse transcriptase that encodes resistance to 2',3'-dideoxyinosine and cross-resistance to 2',3'-dideoxycytidine. J. Virol. 66, 7128−7135 (1992). | PubMed | ISI | ChemPort |
- Schinazi, R.F. et al. Characterization of human immunodeficiency viruses resistant to oxathiolane-cytosine nucleosides. Antimicrob. Agents Chemother. 37, 875−881 (1993). | PubMed | ISI | ChemPort |
- Tisdale, M., Kemp, S.D., Parry, N.R. & Larder, B.A. Rapid in vitro selection of human immunodeficiency virus type 1 resistance to 3'-thiacyti-dine inhibitors due to a mutation in the YMDD region of reverse transcriptase. Proc. natn. Acad. Sci. U.S.A. 90, 5653−5656 (1993). | ChemPort |
|
